PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35504143-0	2022	Pirfenidone mitigates TGF-beta1-mediated fibrosis in an idiopathic inflammatory myositis-associated interstitial lung disease model.	pirfenidone	0-11	transforming growth factor, beta 1	Mus musculus	22-31	
35504143-11	2022	Pirfenidone attenuated IIM-associated ILD with anti-inflammatory properties evidenced by decreased peribronchial inflammation and TGF-beta1 in bronchoalveolar lavage fluid.	pirfenidone	0-11	transforming growth factor, beta 1	Mus musculus	130-139	
35504143-12	2022	Likewise, pirfenidone attenuated pulmonary fibrosis by fine-tuning TGF-beta1-mediated epithelial-to-mesenchymal and fibrotic signaling pathways; pro-fibrotic SMAD3, ZEB2 and STAT1 expression and activation were decreased, whereas anti-fibrotic SMAD2 activation was increased.	pirfenidone	10-21	transforming growth factor, beta 1	Mus musculus	67-76	
35504143-12	2022	Likewise, pirfenidone attenuated pulmonary fibrosis by fine-tuning TGF-beta1-mediated epithelial-to-mesenchymal and fibrotic signaling pathways; pro-fibrotic SMAD3, ZEB2 and STAT1 expression and activation were decreased, whereas anti-fibrotic SMAD2 activation was increased.	pirfenidone	10-21	SMAD family member 3	Mus musculus	158-163	
35504143-12	2022	Likewise, pirfenidone attenuated pulmonary fibrosis by fine-tuning TGF-beta1-mediated epithelial-to-mesenchymal and fibrotic signaling pathways; pro-fibrotic SMAD3, ZEB2 and STAT1 expression and activation were decreased, whereas anti-fibrotic SMAD2 activation was increased.	pirfenidone	10-21	zinc finger E-box binding homeobox 2	Mus musculus	165-169	
35504143-12	2022	Likewise, pirfenidone attenuated pulmonary fibrosis by fine-tuning TGF-beta1-mediated epithelial-to-mesenchymal and fibrotic signaling pathways; pro-fibrotic SMAD3, ZEB2 and STAT1 expression and activation were decreased, whereas anti-fibrotic SMAD2 activation was increased.	pirfenidone	10-21	signal transducer and activator of transcription 1	Mus musculus	174-179	
35504143-12	2022	Likewise, pirfenidone attenuated pulmonary fibrosis by fine-tuning TGF-beta1-mediated epithelial-to-mesenchymal and fibrotic signaling pathways; pro-fibrotic SMAD3, ZEB2 and STAT1 expression and activation were decreased, whereas anti-fibrotic SMAD2 activation was increased.	pirfenidone	10-21	SMAD family member 2	Mus musculus	244-249	
35504143-13	2022	This study unravels for the first time that pirfenidone has the potential to fine-tune TGF-beta1 fibrotic signaling in IIM-associated ILD.	pirfenidone	44-55	transforming growth factor, beta 1	Mus musculus	87-96